Protein biomarker testing in urine for patients presenting with morbidities associated with high risk to undergo acute kidney injury (AKI) is a new option for early diagnosis of kidney stress und would therefore be helpful to mitigate injuries by early intervention strategies. Background: Acute kidney injury (AKI) is a life threatening condition. Despite intensive care treatment the occurrence cannot be predicted as very little indicators exist for direct measurement when tubular epithelial cell injury takes place. We therefore searched for novel peptide indicators expressed at intracellular level at the proximal kidney tubule for its appearance in urine samples. Objectives: Establishing a test for urinary C20orf116 protein measurement. Patients and Methods: Generation of immunoreagents against C20orf116 also named DDRGK1. These were used to measure its presence in urine collected at 8-24 hours interval in a prospective study from 99 ICU patients at 4-6 time points. These patients received therapy because of serious infection and were categorized into 4 groups.
several proteins of unknown function had been structurally defined and its topology of expression has been elucidated through the human protein atlas (http://www.proteinatlas.org/) we have been motivated to look at kidney specific proteins which might appear in urine upon cellular disintegration in proximal kidney tubules the site of acute kidney injury (AKI). This represents an important topic as AKI accounts for a serious condition that affects many intensive care unit (ICU) patients with devastating consequences (8) (9) (10) (11) . Sepsis and septic shock remain the most common contributing factors in the development of AKI in ICU (8) . Until recently, the development of AKI in sepsis patients was considered to be a condition of hemodynamic origin (12) . However, recent data suggest that there is no impairment of the renal blood flow (RBF) in these patients. At the contrary, recent work has demonstrated that RBF remained normal or even increased during severe sepsis (13) . Another mechanism that might be implicated in the development of septic AKI is apoptosis (14, 15) . Septic AKI accounts for close to 50% of cases of AKI in ICU (8) . The mortality rate of AKI varies with the severity of AKI from 20.9% to 56.8%, compared with 8.4% among patients without AKI (16) . Therefore, early prediction and detection of AKI is of vital importance to prevent its progression and thereby, possibly to improve its outcome (17) . Consistent with this are the animal models which strongly suggest that early treatment is the key to prevent AKI (18, 19) . The detection of AKI is based on serum creatinine (sCr) rise and reduction of urine output. However, this marker has limitations as a marker of glomerular filtration rate (GFR) because substantial kidney injury may have already occurred by the time sCr increases (20) and urine flow decreases. Therefore, reliable biomarkers that predict AKI before these two late indicators become evident have to be identified. In this respect, diverse urinary proteins have been evaluated as non-invasive indicators of AKI (1) (2) (3) (5) (6) (7) 21) and have already provided further insight. Recently, we have cloned a novel protein, encoded by open reading frame 116 at chromosome 20 (known also as DDRGK1 and C20orf116), and demonstrated its abundant expression in the kidney and in the proximal tubular cells (22) . In addition, it has been suggested that this protein is not a secreted moiety but rather resides at the endoplasmic reticulum (ER) due to its signal peptide (23) . In our immunohistochemical analysis the protein was found in the lumen of some kidney tubules. It laid the foundation for the idea to test whether C20orf116 can be detected in human urine samples. Following initial experiments which showed C20orf116 in critically ill patient's urine, we conducted a study comparing urine samples from healthy volunteers with critically ill patients. This was performed at our ICU in a prospective study and urinary C20orf116 was compared with routine kidney function tests and the clinical course of patients.
Objectives
Early diagnosis of kidney cell damage is of importance in medical care therefore we searched for novel urinary biomarkers indicative for tubular cell injury.
Patients and Methods

Urine collection
Catheter urine or clean catch urine samples were centrifuged (3000 rpm at 4°C for 10 minutes) to remove cell components and stored at -20°C for further use. The study design suggested urine sampling at admission/diagnosis and at 8-12, 24, 48, 72 and 96 hours following ICU treatment. All ICU patients were diagnosed with septicemia or severe infections (pneumonia). ICU patients were categorized according to RIFLE staging (R = risk, I = injury, F = failure, L = loss, E = end stage disease) into four groups 1) developing AKI grade F and L and requiring renal replacement therapy (RRT, n = 10), 2) AKI grade I upon preexistent kidney disease with sCr >2.5 m/dl (n = 6), 3) AKI grade R or I (n = 11) and group 4) all remnants (n = 72) not fulfilling AKI according to RIFLE criteria but with sCr rise 1.2-1.4 fold (n = 52). Healthy individuals (n = 48) collected 4 individual urine samples by clean catch over a period of at least 48 hours. The four time points of measurement were chosen in a way that from each urine donor a morning urine sample had been collected and the urine collection time interval was spread over a period of at least 48 hours.
Generation of C20orf116 overexpressing cell line
The full coding sequence of C20orf116 was cloned into the pMSCV plasmid and lentivirus particles were generated essentially as described earlier (24) . The cell line C-643 was transduced and chemoselected using puromycine (4 ng/mL).
Direct ELISA
High binding E.I.A/R.I.A plates were coated over night at 4°C with 100 µl recombinant C20orf116 (12.5 ng/mL in PBS) generated as a His-tag fusion protein in Sf9 insect cells as described earlier (22 
Western blot analysis
Urine samples (30 µl) were loaded after denaturation in SDS sample buffer onto 10% SDS-PAGE gel. After electrophoresis, the proteins were electrotransferred onto a nitrocellulose using a semidry blotting device. Following the blocking step, the blotted membrane was consecutively exposed to the primary Ab (rabbit anti-C20orf116 Ab; diluted 1:2000, overnight at 4°C) and to the secondary Ab (HRP-conjugated goat antirabbit Ab; diluted 1:5000, 50 minutes at RT). Between each incubation step, the blotted membrane was washed in PBS containing 0.1% Tween 20. Antigen visualisation was performed by chemiluminescence using lumi-imager F1 (Roche).
Urine ELISA assay
High binding E.I.A/R.I.A plates (Costar, Cambridge, MA, USA) were coated with purified anti-C20orf116 IgG for 4 hours at RT or overnight at 4°C. After a brief wash, 50 µl urine was dispensed into the 50 µl of blocking solution (KPL) pre-applied onto the multi-well dish. The plate was then incubated at RT for 2 hours under constant shaking including a standard series at each plate. After a brief wash with PBS, biotinylated rabbit anti-C20orf116 IgG and biotinylated mAb A2 was applied (dilution 1:2000 in PBS/rabbit serum) and incubated for 1 hour at 37°C. Following a second washing step (4 washes with 300 µl PBS) NeutrAvidin (Stratagene ® , La Jolla, CA, USA) (1/5000 in 0.5x blocking solution) was added and incubated at RT for 45 minutes. Wells were washed with PBS (4 times with 300 µl PBS) and developed with two component TMB substrate (KPL Inc. Gaithersburg, MD, USA) for 15 minutes at RT in the dark. The reaction was stopped by adding 100 µl 1M H 3 PO 4 and read at 450 nm with the ELISA reader (Power wave x , Bio-tek instruments, Inc., USA) at 450 nm. The concentrations were then calculated according to the standard curve. All samples were analyzed in duplicate. In total 1280 samples had been available for testing.
Biotinylation of antibodies
Protein G-Sepharose eluted rabbit IgG or mAb A2 was dialyzed against PBS for 3 days at 4°C and at least three changes of dialysis fluid. D-Biotinoyl-ε-Aminocaproic Acid N-Hydroxysuccinimide Ester (Roche Diagnostics, Mannheim, Germany) was dissolved in DMSO (30 mg/ml) and biotin was added to the antibody solution under constant stirring in 15 fold molar excess. The biotinylation was carried out at RT over 2 hours and free biotin was removed from the antibody by gel filtration chromatography using Sephadex ® G-25 (Boehringer Mannheim, Mannheim, Germany).
Ethical issues
The research followed the tenets of the Declaration of Helsinki. Informed consents were obtained. All patients took part in this study voluntary. Sample analysis was carried out by blinded investigators each in duplicate. The research was approved by the ethical committee of the Medical University of Vienna (ethic code: 721/2007).
Statistical analysis
The 5th to 95th percentile of C20orf116 values are demonstrated in Whiskers blots. Differences between multiple groups were calculated with SPSS using analysis of variance (ANOVA) with correction for post hoc analysis. Statistical significance was defined when P < 0.05. The graphic representation was performed using GraphPad Prism (La Jolla, CA, USA).
Results
High throughput gene expression analysis has generated extensive data sets on uncharacterized gene transcripts in various tissue types and disease processes. In order to obtain further information on till now undefined protein function we generated immunoreagents and established quantitative methods for mRNA and protein expression of C20orf116 also named Dashurin and DDRGK1. The presence of the protein was observed in kidney tubules in tissue sections. This has been established by immunofluorescence analysis of kidney cryosections (Figure 1 ). C20orf116 expression was also found in epithelia of urinary bladder and the urethra (data not shown). As already demonstrated in previous work the protein is not only expressed in kidney and urinary tract but is also found in the central nervous system, liver, placenta and heart (22, 23, 25) .
ELISA quantification of urinary C20orf116
Motivated by a striking kidney tubule expression pattern as mentioned above we established a urinary ELISA method to measure C20orf116 in urine samples collected at 4-6 time points from intensive care patients (n = 99) and we compared these with healthy donor urine which were collected at four different time points. Equivocally, all 48 healthy donors had no detectable level by our ELISA method. In the control group only healthy donors fully active in various professional backgrounds with sCr levels within the normal range were included. In contrast to healthy controls 10 ICU patients tested high (3210 ± 1350 ng/mL) for C20orf116 ( Figure 2 ) at least 24 hours ( Figure 3A ) before sCr rise who had required RRT and were graded F or L according to RIFLE. Only one patient survived this disease episode. The patient who recovered is depicted at ( Figure 3C ). Six patients with pre-existing renal disease (sCr >2.5) developing AKI on chronic kidney disease (CKD) showed much lower level of C20orf116 (33 ± 19 ng/ mL) (Figure 2 ), these patients were included in the group AKI on CKD (Figure 2 ). Eleven patients developed AKI grade R with C20orf116 (66 ± 43 ng/ml) ( Figure 2 ) and only 4 tested positive out of them. Finally out of 72 remaining patients who did not reach strict AKI criteria but developed 1.2-1.4 fold sCr rise 25 showed detectable C20orf116 (18 ± 12 ng/ml) ( Figure 2 ). All of them recovered. C20orf116 levels are statistically significantly different among the 5 groups (ANOVA, P < 0.001). The post hoc test revealed again a statistically significant higher concentration of C20orf116 product in the group graded AKI, F or L when compared with other ICU groups and healthy controls (Tukey HSD, P < 0.001). One of the patients in the group who did not reach AKI criteria showed high levels due to a nonexplainable reason undergoing a sCr rise of 1.3 fold which was entirely reversible under intensive care treatment. She did not recover from infectious episodes for more than 5 months but was discharged from ICU after 1 month. Her kidney function tests stayed within the normal range. Most importantly, in patients with previously intact kidney function high urinary levels of C20orf116 were detected 24-48 hours earlier before a rise in sCr could be observed ( Figures 3A and B) . Urine C20orf116 testing was carried out at 4-6 time points following diagnosis or admission to ICU as depicted in the methods section. As sample analysis was carried out in retrospect no further samples were available for testing at the time-point of C20orf116 measurement. SCr values were taken from the hospital routine data and used together with fluid output and disease records to evaluate grading and course of AKI. Levels of C20orf116 in urine seemed to predict 69 severity of kidney injury ( Figure 2 ) and preceded sCr rises by 12-48 hours ( Figure 3A -C) but high levels in some of the patients were still found when sCr returned to normal range and urine output increased.
Immunoblot characterization of urinary C20orf116
Earlier work has demonstrated that the DDRGK1 protein migrates at the SDS-PAGE at about 40 kDa (22, 23) which is higher than the predicted molecular size would be expected. This was not only our observation but has also been described by Wu et al (23) . Assuming that the urinary C20orf116 would not represent a physiological release product but rather a fragment which is liberated upon cell injury we performed multiple immunoblots of lyophilized urine samples and urine with high C20orf116 level according to ELISA tests derived from various ICU patients. A representative picture is demonstrated at Figure 4 , various fragments of C20orf116 have been found in urine. The fragments seen at the blot were dependent on the antibody used for immunodetection of the urinary protein. In each experiment recombinant C20orf116 was included. The antibody used for immunoblotting was also essential for our ELISA testing and was included in each of the tests.
Tissue culture experiments
Although all data pointed towards detectability of the protein upon cellular breakdown we intended to assure that C20orf116 would not be a secretion product. Therefore we generated an over-expressing cell line as indicated in the methods section and tested whether the protein was detectable in tissue culture supernatant or not. Secretion of detectable amount could be excluded whereas intracellular protein was abundant which confirms data obtained by another group (23).
Discussion
In this study we present data from appearance of C20orf116 in body fluids such as urine in episodes of critical conditions in intensive care patients. This has been made possible after generating specific immunoreagents (polyclonal and monoclonal antibodies) against this protein. (23) . In consequence, our data point towards cellular disintegration which is then followed by release of this protein into the urine. To confirm these results we performed overexpression experiments and measurement in the tissue culture supernatant which revealed negative results confirming earlier data (23) . In addition our observation of not detectable levels of C20orf116 in urine with the ELISA test of healthy individuals is further confirmatory that the protein fulfils its physiological function as a genuine intracellular protein. It therefore has to be assumed that appearance of C20orf116 in urine at high quantities is indicative for disintegration of cells at the tubular epithelium.
As all ICU patients were tested from urine obtained from a catheter placed through the urethra into the urinary bladder it has to be assumed that minor lesions of the urinary bladder do not contribute much to the level of C20orf116 in urine.
Taking into consideration that various other parameters such as IL-18, NGAL cystatin C (1,2,4,5,21) have been associated with AKI we have continuously attempted to search for other kidney born parameters which can be easily detected in urine before irreversible damages occur. We have now found one which seems to provide promising results especially as an early marker. One serious obstacle of this test represented the precipitation of recombinant protein upon freezing which had to be used for the standard curve. This problem could be resolved by dissolving the protein in 7M urea and then diluting it in urine. The urinary matrix seems to keep the protein better accessible to immunoreagents than any buffer used for recombinant protein solubilization. Having demonstrated that fragments of C20orf116 might not be detected in all of the various samples we have been motivated to generate monoclonal antibodies against C20orf116 (aa 28-314). However, these antibodies did not prove usable in sandwich capture ELISA but together with the polyclonal antibody these might provide greater sensitivity in further experiments. Therefore polyclonal rabbit antibodies had to be produced for clinical specimen testing. These detected various fragments which originate from degradation during cell fragmentation and urine flow. Contamination with cells can be excluded due to the fact that each urine sample had been centrifuged as indicated in the methods section prior to freezing. The observation that a subgroup of ICU patients with minor changes in sCr not fulfilling criteria of overt AKI show C20orf116 secretion in urine might indicate that tubular cell injury might occur silently not detectable by routine clinical parameters. In this direction observations by others showed that even minor changes in sCr while under ICU treatment will be of relevance for the further life span and patient outcome (26).
Conclusions
In conclusion we demonstrate that this novel protein expressed highly at the proximal kidney tubule might be promising to detect kidney damage which might be induced by potential nephrotoxic agents such as antibiotics and contrast agents and endogenous conditions at serious infections. However, most likely it will have to be combined with other novel markers such as Timp 2 and IGFBP 7 (5), KIM-1, neprilysin (27) or MIOX and others already or not yet characterized.
Limitations of the study
Antibodies which are necessary for such measurement are not commercially available, furthermore the protein might be a too sensitive marker as a certain patient group presented with detectable levels without manifestation of any AKI stage. Comparison with other available biomarkers was beyond the borders of this study.
